-
Hoth Therapeutics Leverages OpenClaw™ AI Platform to Advance Drug Discovery
NASDAQ: $HOTH Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a significant strategic advancement with the deployment of OpenClaw™, its new, advanced AI-enabled computational platform. This move signifies a major commitment to integrating artificial intelligence into the core of its drug discovery and development…
-
Alliance for Genomic Discovery Scales Up: Regeneron Joins, Multiomic Data Initiative Launched
NASDAQ: $ILMN Genomic Research Reaches New Heights with Expansion and Proteomic Integration The landscape of genomic discovery is undergoing a significant transformation with major developments announced by the Alliance for Genomic Discovery (AGD), a collaboration spearheaded by Illumina, Inc. and Nashville Biosciences, LLC (NashBio). Two key announcements signal a massive leap forward: the addition of…
-
Promising Early Results: LYMPHIR™ Shows Potential to Enhance CAR-T Therapy in High-Risk DLBCL
NASDAQ: $CTOR Citius Oncology, Inc., a key player in oncology biopharmaceuticals and a subsidiary of Citius Pharmaceuticals, Inc., recently shared encouraging topline safety and efficacy results from an investigator-initiated Phase 1 trial. This study explored the utility of LYMPHIR™ (E7777, denileukin diftitox?cxdl) when administered as a preparatory treatment before commercial CD19-directed CAR-T cell therapy for…
-
Hoth Therapeutics Leverages OpenAI API to Accelerate Development of Orphan Oncology Program, HT-KIT
NASDAQ: $HOTH Hoth Therapeutics, Inc., a biopharmaceutical company dedicated to patient-focused therapies, recently announced a significant strategic move: the deployment of the OpenAI API to bolster the development of its orphan-designated therapy, HT-KIT. This innovative integration targets rare and aggressive KIT-driven cancers, marking a forward-thinking approach to drug development within the oncology space. AI Integration…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 03-01-2026 TO 03-07-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-22-2026 TO 02-28-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$ALDX, $ALXO, $BBIO, $CGEN, $FULC, $GANX, $IMRX, $TARA, $XNCR, ASCO Genitourinary Cancers Symposium, biopharmaceutical, clinical-research, fda, new drug application, Oppenheimer 36th Annual Healthcare Life Sciences Conference, pr-newswire, press-releases, Wells Fargo Executive Biotech Summit, World ADC London 2026 -
FDA Approves Groundbreaking All-Oral, Fixed-Duration Treatment for Previously Untreated CLL
NYSE: $ABBV A Significant Advance in Chronic Lymphocytic Leukemia Treatment The U.S. Food and Drug Administration (FDA) has granted approval for the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients newly diagnosed with chronic lymphocytic leukemia (CLL). This pivotal decision, supported by robust data from the Phase 3 AMPLIFY trial, introduces the first…
-
10x Genomics Scheduled to Present at 46th Annual TD Cowen Health Care Conference
NASDAQ: $TXG 10x Genomics, Inc., a prominent innovator in the fields of single cell and spatial biology, has confirmed its participation in a significant industry event next month. The company announced that key members of its management team are slated to present at the highly anticipated 46th Annual TD Cowen Health Care Conference. The scheduled…
-
Compugen Set to Present at Key Investor Conferences in Early 2026
NASDAQ: $CGEN Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline. The first…